It is a critical step in tissue repair because the new vessels deliver oxygen, nutrients, and immune cells to the site of injury
PMID: 27474730
2/5/2025 Michelle Brugman Loving it
Encouraging Robust Research: Supporting independent, high-quality research on BPC-157 can help determine its true efficacy and safety
Several retrospective studies associated the drug class with lower glaucoma risk and reduced ocular hypertension incidence, while preclinical work demonstrated reduced retinal ganglion cell loss and optic nerve damage in experimental models. The experimental literature also points to inflammatory modulation, oxidative stress reduction and retinal ganglion cell survival pathways as possible mechanisms. Smaller studies evaluating IIH and DED reported reductions in intracranial pressure and improved ocular surface parameters, respectively, among treated patients. READ MORE: Blinding Disease-Weight Loss Drug Link: EMA Announces Start of Semaglutide Investigation The evidence base still has limits The review flagged recurring methodological constraints across the literature: reliance on retrospective EHR analyses and ICD-based coding, heterogeneous ocular endpoints, inconsistent imaging and limited longitudinal follow-up
These include individuals with a personal or family history of medullary thyroid carcinoma, those with Multiple Endocrine Neoplasia syndrome type 2, and anyone with known hypersensitivity to semaglutide or product components
